Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Oct 16, 2020
Trial Information
Current as of June 28, 2025
Withdrawn
Keywords
ClinConnect Summary
The current prospective observational study proposes to use intra-patient comparisons of peak changes in renal function (serum creatinine) in absence of- and post- intravascular iodinated contrast administration, to elucidate the relationship between renal function and contrast administration in elective patients with eGFR \<30 mL/min/1.73m2. The effects of contrast administration on risk of 1-month dialysis and mortality will also be evaluated.
Daily serum creatinine assays will be done 1. during 5 days before contrast (= in absence of contrast), 2. during 5 days after contrast (= post-co...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • eGFR \<30 mL/min/1.73m2 in absence of dialysis
- • referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+
- Exclusion Criteria:
- • age \<18 years
- • dialysis or pre-dialysis
- • intravascular contrast administration \<30 days before the first baseline measurement
- • emergency or intensive care status
- • inability to complete follow-up
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials